Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D02027 (Tranilast)
 205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Accelerated coronary arteriosclerosis remains a major problem for the long-term survival of cardiac transplant recipients. However, the pathogenesis of graft vasculopathy is poorly understood and there is no effective therapy. Tranilast is a promising drug that may prevent post-angioplasty restenosis. Here, we investigated whether orally administered tranilast inhibits the development of intima hyperplasia in a mouse model of cardiac transplantation. Cardiac allografts from BALB/c mice were transplanted heterotopically into C3H/He mice. Mice were administered either vehicle or tranilast everyday by gavage. Morphometrical analysis of the cardiac allografts harvested at 2 months revealed that the administration of tranilast significantly reduced the development of coronary atherosclerosis. In the mice treated with tranilast, up-regulation of the cyclin-dependent kinase inhibitor p21 was observed in the allografts, accompanied by a reduced number of proliferating cells. Tranilast also suppressed transforming growth factor-beta (TGF-beta) expression. Tranilast may be effective in preventing transplant-associated arteriosclerosis through its anti-inflammatory and anti-proliferative effects.
 ...
PMID:Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. 1175 48

Kissei, in collaboration with SmithKline Beecham, is developing tranilast (Rizaben) as a prophylactic agent for restenosis, following percutaneous transluminal coronary angioplasty (PTCA). As of May 1997, tranilast was awaiting approval in Japan as an oral formulation given for three months following PTCA [246273], [248281]. The agent has been launched for use in allergic rhinitis, asthma and atopic dermatitis. Analysts had expected the early approval of Rizaben for PTCA-associated restenosis. However, due to delays by the Ministry of Health and Welfare, it is unlikely that Rizaben will be approved until the end of 1998. Sales of Rizaben for the treatment of its launched indications did not reach company expectations. The companies are also developing tranilast, in a nasal spray formulation, as a potential treatment for allergic rhinitis. The drug is in phase II trials for this indication [262810]. EP-00588518 from Kissei discloses the use of tranilast for the treatment of restenosis. Kissei has also filed patents disclosing the use of tranilast for arteriosclerosis (JP-09227371) and diabetic retinopathy (WO-09729744).
 ...
PMID:Tranilast Kissei Pharmaceutical. 1846 19